Er-Miao-Fang Extracts Inhibits Adipose Lipolysis and Reduces Hepatic Gluconeogenesis via Suppression of Inflammation

Wenjun Zhao1,2, Xin Feng1, Baolin Liu3, Jiechen Xian4* and Ning Zhang1*

1 Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai, China,
2 Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China, 3 Clinical Metabolomics Centre, China Pharmaceutical University, Nanjing, China, 4 Engineering Research Center of Modern Preparation Technology of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

High-fat-diet (HFD) feeding induces adipose dysfunction. This study aims to explore whether the Traditional Chinese Medical prescription Er-Miao-Fang could ameliorate adipose dysfunction and prevent hepatic glucose output. Short-term HFD feeding induced adipose lipolysis accompanied with enhanced hepatic glucose output in mice. Adipose lipolysis is initiated by cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling. Oral administration Er-Miao-Fang inhibited inflammation in adipose tissue by dephosphorylation of JNK and reducing TNF-α and IL-1β production, and thus preserved phosphodiesterase 3B (PDE3B) induction, contributing to preventing cAMP accumulation. As a result, from suppression of PKA activation, Er-Miao-Fang reduced fatty acids and glycerol release from adipose tissue due to the inhibition hormone-sensitive lipase (HSL). By blocking the traffic of fatty acids and inflammatory mediators from adipose tissue to the liver, Er-Miao-Fang attenuated hepatic cAMP/PKA signaling by protecting phosphodiesterase 4B (PDE4B) induction from inflammatory insult, and thereby reduced hepatic glucose production by suppression of hepatic glucagon response in HFD-fed mice. In conclusion, Er-Miao-Fang prevented adipose lipolysis by suppression of inflammation, contributing to reducing excessive hepatic glucose output. These findings present a new view of regulating gluconeogenesis and provide the guiding significance for the regulation of multi-link targets with Traditional Chinese Medicine.

Keywords: Er-Miao-Fang, inflammation, PDE3B, PDE4B, glucagon, gluconeogenesis

INTRODUCTION

Adipose tissue functions as a site of fat storage, while adipose dysfunction in obesity and diabetes induces lipolysis and increases circulating free fatty acids to promote ectopic fat deposits. It is generally accepted that lipid accumulation in the liver and muscle is the main cause for insulin resistance (Lafontan and Girard, 2008; Kowalski et al., 2015; Zhao et al., 2016). The action of insulin...
in liver is to suppress hepatic glucose production and lipolysis-induced lipid accumulation in the liver is shown to attenuate insulin sensitivity and increase hepatic glucose production, responsible for hyperglycemia during fasting in diabetes (Perry et al., 2014). These events suggest the functional interaction between adipose lipolysis and abnormal hepatic gluconeogenesis.

Several hormones and effectors can induce lipolysis in adipose tissue though the activation of cAMP-dependent protein kinase A (PKA), in which hormone-sensitive lipase (HSL), a key enzyme in the mobilization of fatty acids from stored triacylglyceride (TG), is activated (Greenberg et al., 2001; Greenberg et al., 2011; Schweiger et al., 2014). Insulin regulates post-prandial glucose levels by promoting glucose disposal, while maintains glucose homeostasis during fasting conditions by promoting hepatic glucose output. Several lines of evidence demonstrate that enhanced hepatic glucagon response is responsible for hyperglycemia during fasting (Unger and Cherrington, 2012). In liver, hepatic gluconeogenesis responded to glucagon is also initiated by cAMP/PKA signaling, transcriptionally regulating gene encoding to gluconeogenesis enzymes, including G6Pase and PEPCK (Leahy et al., 1999; Streeper et al., 2001; Yang and Yang, 2016). Blocking cAMP/PKA signaling suppresses HSL activation to inhibit lipolysis (Zha et al., 2016). Hepatic glucagon response is restrained by blocking cAMP/PKA signaling and inhibiting transcriptional regulation of G6Pase and PEPCK (He et al., 2009). All these well elucidate that cAMP/PKA signaling plays a vital role in regulation of lipid and glucose metabolism.

As a second messenger, cAMP is synthesized by adenylyl cyclase (AC) while phosphodiesterases (PDEs) could prevent cAMP accumulation through degradation. PDEs are invariably diverse, for instance, PDE3 and PDE4 provide the major portion of cAMP hydrolyzing activity in most cells (Francis et al., 2011). PDE3B is proposed to be the predominant isoform of PDEs in adipose tissue. Inflammation is demonstrated to regulate PDE3B induction. TNF-α inhibited PDE3B activity with suppression of PDE3B induction and thus increases lipolysis, indicative of the involvement of inflammation in lipolysis (Mei et al., 2002). In the liver, the members of the PDE3 and PDE4 subfamilies are both expressed. While PDE4B is the predominant regulator for hepatic cAMP degradation (Miller et al., 2013). Similarly, it is documented that inhibiting cAMP accumulation by preserving PDE4B activity contributes to suppress hepatic glucagon response (Xiao et al., 2017). So, decreased PDEs expression is associated with the dysfunction in adipose and liver, and these events emphasize the possible relevance of inflammation in the regulation of fatty acid and hepatic glucagon response.

Er-Miao-Fang is a famous Traditional Chinese Medical prescription first recorded in Dan Xi Xin Fa in 1481. It is composed of two medicinal herbs: Phellodendron chinense Schneid and Atractylodes lancea (Thunb.) DC or Atractylodes chinensis (DC.) Koidz and it has been widely used to treat arthritis, urinary tract infections, and diarrhea for decades. Studies about the pharmacological mechanism of this ancient prescription are performed mainly focused on its anti-inflammatory activity (Chen et al., 2014; Bae et al., 2015). The alkaloids are the main components in the Er-Miao-Fang extracts with abundant berberine (4.019%) and phellodendrine (0.371%), the main effective ingredients (Feng et al., 2017). Berberine was documented to reduce lipid droplet accumulation and improve insulin sensitivity (Lee et al., 2006). Treatment of berberine reduces the levels of fasting blood glucose and inhibits the expression of G6Pase and PEPCK (Wei et al., 2016). Phellodendrine ameliorated oxidative stress by downregulating NF-κB phosphorylation (Li et al., 2016). These studies suggest the potential role of Er-Miao-Fang extracts in the metabolism disorder. Hence, in this study, we explored the possible pharmacological action of Er-Miao-Fang extracts in regulation of lipolysis and hepatic gluconeogenesis by inhibiting adipose inflammation.

**MATERIALS AND METHODS**

**Preparation of Er-Miao-Fang**
Phellodendron chinense Schneid and A. lancea (Thunb.) DC. were purchased from Shanghai Kangqiao Chinese Medicine Yinpian Co., Ltd. (Shanghai, China) and authenticated by Yan Ke (Experiment Center for Teaching and Learning, Shanghai University of Traditional Chinese Medicine). Qualities of the crude drugs meet the standards of “Pharmacopoeia of the People’s Republic of China” (2015 edition). P. chinense Schneid with the same weight of A. lancea (Thunb.) DC. was boiled three times with 10 times the volume (v/w) of 70% ethanol for 2 h each time after soaking 30 min. The extracts were filtered, concentrated and decompression vacuum drying fewer than 65°C was adopted. Er-Miao-Fang extracts were prepared and the yield was 24.7%. The chemical components of Er-Miao-Fang extracts were analyzed by UPLC-MS/MS, and the followings are the chief six components and contents tested in the extracts: berberine, 4.019%; phellodendrine, 0.371%; chlorogenic acid, 0.158%; ferulic acid, 0.141%; magnoflorine, 0.107 %; and palmatine, 0.039% (Feng et al., 2017).

**Reagents**
Metformin (purity ≥ 99%) was purchased from Sangon Biotech (Shanghai, China) and dissolved in 0.3% (w/v) sodium carboxymethylcellulose (CMC-Na) for animal administration or in dimethyl sulfoxide (DMSO) for cell experiment [the final concentration of DMSO was 0.1% (w/v)]. Glucagon (purity ≥ 98%) was obtained from Kinase Chemicals Ltd. (Suffolk, United Kingdom). Sodium pyruvate (purity ≥ 99%) was provided by Sigma-Aldrich (Shanghai, China). Palmitate (PA, Sinopharm, Shanghai, China) was dissolved in ethanol to prepare 200 mM stock solution, and then diluted with medium containing 10% non-esterified fatty acid (NEFA)-free bovine serum albumin (BSA) before use (w/v, 1:19). Mouse cAMP, AMP, TNF-α, and IL-1β ELISA kits were provided by Shuojia Biotechnology Co., Ltd. (Shanghai, China). The following items were purchased from the cited commercial sources: anti-phospho-(Ser/Thr) PKA substrate (9621), anti-phospho-HSL (Ser660) (4126), anti-HSL (4107), anti-phospho-SAPK/JNK (Thr183/Tyr185) (4668), anti-SAPK/JNK (9252), anti-β-actin (4970), Cell Signaling Technology (Beverly, MA, United States);
anti-TNF-α (ab6671), anti-CREB (phospho S133) (ab32096), anti-CREB (ab32515), goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Abcam (Cambridge, MA, United States); PDE3B (H-300) (sc-20793), PDE4B (H-56) (sc-25812), Santa Cruz Biotechnology (Dallas, TX, United States); peroxidase-conjugated affinipure goat anti-Rabbit IgG (H&L) (111-035-003), Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, United States); mouse IL-1β (AF-401-NA), R&D System (Minneapolis, MN, United States); RNAiso Plus (9108), RT Reagent Kit (RR037A), SYBR® Premix Ex Taq (RR420A), Takara Bio Inc. (Dalian, China).

Animals
Male ICR mice (6 weeks) were purchased from Sino-British Sippr/BK Lab. Animal Ltd. (Shanghai, China, production license: SCXK (Shanghai) 2013-0016). Mice were housed with 12 h light/dark cycles under a constant temperature (22 ± 2°C) and free access to water and food. This study was carried out in accordance with the recommendations of Provision and General Recommendation of Chinese Experimental Animals Administration Legislation. The protocol was approved by Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine.

Mice were fed a regular chow diet or high-fat-diet (HFD) (10% yolk, 10% Lard, 0.2% cholate, 1% cholesterol and 78.8% standard diet, 36.45% Kcal fat) for 10 days (Wang et al., 2016; Zhao et al., 2016) with oral administration of saline, Er-Miao-Fang extracts (1 g/kg) or metformin (200 mg/kg), respectively every day. Adipose tissue was collected after 8 h fasting and blood glucose was assayed with commercial kits following the manufacturer’s instructions (Jiancheng, Nanjing, China).

Preparation of Conditioned Medium (CM) of Adipose Tissue From HFD-fed Mice
Epipidymis adipose tissue was collected from chow-fed or HFD-fed mice and cut into small pieces, then incubated with the same weight in 2 mL DMEM (25 mM glucose, Gibco, Grand Island, NY, United States) containing 10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin) for 24 h at 37°C in a 5% CO2 incubator (Wang et al., 2016; Zhao et al., 2016). Collected the DMEM, centrifuged at 3,000 g for 5 min at 4°C and the supernatant was harvested as conditioned medium (CM). For the preparation of glucose-free CM, the chow-fed or HFD-fed mice adipose tissue was incubated in Krebs-Ringer phosphate-HEPES buffer (KRH buffer, containing 118 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, and 30 mM HEPES, containing 0.5% BSA, pH 7.4). The CM was used to culture hepatocytes to explore the crosstalk between adipose and liver.

Hepatocytes Glucose Output
Hepatocytes were cultured with glucose-free adipose-derived CM or TNF-α antibody (1 µg/mL) and IL-1β antibody (0.6 µg/mL) for 24 h. After washing, the cells were incubated in KRH buffer supplemented with 20 mM pyruvate, with or without 100 nM glucagon for 6 h. The supernatant was collected for glucose analysis with commercial kits.

Quantitative Real Time RT-PCR
Total mRNA was extracted from tissue or cells using RNAiso plus following the manufacturer’s protocol and cDNA synthesis were preformed using RT reagent kit. Relative cDNA levels were determined using the SYBR Premix Ex Taq and amplified with ABI 7500 system. Target mRNA was normalized by ribosomal 18s RNA, an endogenous control. PCR primers were used as follows: mouse PGC-1α (134 bp), Forward Primer: 5’-TATGGA GTGACATAGAGTGTGCT-3’, Reverse Primer: 5’-CCACTTC
AATCCACCCAGAAAG-3′; mouse Pepck (159 bp), Forward Primer: 5′-CTGCATAACGGTGACTTC-3′, Reverse Primer: 5′-CAAGAAGCTCCGTACTCC-3′; mouse G6pase (G6pc, 173 bp), Forward Primer: 5′-CGACTCCGTATCTCCAA GTGA-3′, Reverse Primer: 5′-TGTGAAACCTGTCGACCA A-3′; mouse 18s RNA (151 bp), Forward Primer: 5′-GTAAACCC GTTGAACCCCAAT-3′, Reverse Primer: 5′-CCATCCCAATCG GTAGTAGCG-3′. Relative quantification was calculated based on the following equation: relative quantification = 2^{\Delta \Delta C_t}. C_t is the threshold cycle to detect fluorescence.

**Western Blot Analysis**

Tissue or cells were homogenized in RIPA lysis buffer with PMSF (RIPA: PMSF = 100:1, v/v). The lysates were centrifuged for collection of supernatants. Bicinchoninic acid (BCA) Protein Assay Kit (Beyotime, Haimen, China) was used to test the supernatant proteins contents. The protein samples were separated by 10% SDS-PAGE, and transferred to PVDF membranes (Millipore Co., Ltd. MA, United States), blocked with 5% BSA/TBST buffer (5 mM Tris-base, pH 7.6, 136 mM NaCl, 0.05% Tween-20), immunoblotted with primary and secondary antibody. ECL Western Blotting Detection System and Image-Pro Plus 6.0 software (IPP 6.0, IPWIN Application, Inc., Rockville, MD, United States) was applied to analysis antibody-antigen complexes. The original images are provided as Supplementary Image 1.

**Statistical Analysis**

All the results were expressed as mean ± SD and were subjected to one-way ANOWA analysis of variance followed by Student-Newman-Keuls multiple comparison test if significant (IBM SPSS Statistics 21.0, SPSS Inc., Chicago, IL, United States). \( p < 0.05 \) was considered statistically significant.

**RESULTS**

**Er-Miao-Fang Attenuated Lipolysis in Adipose Tissue**

Short-term HFD feeding induced lipolysis from adipose tissue in mice, demonstrated by increased free fatty acids and glycerol released from isolated epididymal adipose.
tissue, whereas the increased lipolysis was inhibited by oral administration of Er-Miao-Fang extracts during HFD feeding (Figures 1A,B). Because adipose lipolysis is mediated by cAMP/PKA signaling, we examined the effects of Er-Miao-Fang in adipose tissue, and found that HFD feeding increased cAMP accumulation with reducing AMP contents in adipose tissue, whereas the changes were reversed by oral administration of Er-Miao-Fang (Figures 1C,D). HFD feeding induced PKA activation, but Er-Miao-Fang treatment inactivated PKA by dephosphorylation of PKA 62KDa substrate (Figure 1E). These results suggested that Er-Miao-Fang prevented PKA activation by downregulation of cAMP. The phosphorylation of PKA substrate at 62 KDa corresponds to the molecular weight of perilipin. As the major substrate for phosphorylation of PKA, perilipin facilitates lipolysis by HSL hydrolyzing triacylglycerol and diacylglycerol to induce fatty acid release (Miyoshi et al., 2006; Brasaemle, 2007; Gauthier et al., 2008). We found that oral administration of Er-Miao-Fang suppressed HSL activation by dephosphorylation (Figure 1F). These results suggested that Er-Miao-Fang prevented adipose lipolysis by blocking cAMP/PKA signaling. Anti-diabetic agent metformin also effectively reduced lipolysis from adipose tissue in HFD-fed mice.

Er-Miao-Fang Inhibited Inflammation in Adipose Tissue

Adipose dysfunction is associated with inflammation. HFD feeding evoked inflammatory response, whereas Er-Miao-Fang and metformin inhibited inflammation in adipose tissue by attenuating JNK phosphorylation and reducing TNF-α and IL-1β production (Figures 2A–C). The protein expression of PDE3B was decreased in adipose tissue of HFD-fed mice. Nevertheless, administration of Er-Miao-Fang and metformin preserved PDE3B induction (Figure 2D). To investigate the impact of inflammation on lipolysis, we isolated adipose tissue from normal mice and treated with saturated fatty acid palmitate (PA). PA stimulation inhibited PDE3B expression and increased
cAMP accumulation, but these alternations were reversed by Er-Miao-Fang treatment at concentration of 100 µg/ml (Figures 2E,F). Neutralizing pro-inflammatory cytokines TNF-α and IL-1β with special antibodies preserved PDE3B protein expression and decreased cAMP accumulation in adipose tissue (Figures 2E,F).

**Er-Miao-Fang Improved Pyruvate Tolerance in HFD-fed Mice**

High-fat-diet feeding increased fasting blood glucose with glucose intolerance in mice. Oral administration of Er-Miao-Fang and metformin reduced fasting blood glucose with improved glucose tolerance in HFD-fed mice (Figures 3A,B). Meanwhile, we observed that Er-Miao-Fang decreased the levels of blood glucagon without affecting insulin contents in the blood (Figures 3C,D). Pyruvate tolerance test is an indicator of endogenous glucose production since pyruvate load provides the substrate for hepatic glucose production through gluconeogenesis. The changes in glucose levels after a challenge with pyruvate revealed higher glucose levels in HFD-fed mice when compared with chow-fed mice, indicative of impaired pyruvate tolerance (Figure 3E). Oral administration of Er-Miao-Fang and metformin reversed pyruvate intolerance in HFD-fed mice (Figure 3E). Consistent with inhibitory effect on adipose lipolysis, Er-Miao-Fang downregulated the elevated levels of blood free fatty acids and glycerol without affecting other biochemical parameters in the blood (Supplementary Figure 1). These results suggested the inhibitory effect on endogenous glucose production.

**Er-Miao-Fang Blocked Hepatic cAMP and PKA Induction**

Next, we examined hepatic gluconeogenesis in HFD-fed mice, and found that HFD feeding attenuated PDE4B protein expression with cAMP accumulation in the liver (Figures 4A,B). Er-Miao-Fang and metformin preserved PDE4B protein expression.
Zhao et al. Er-Miao-Fang Prevents Hepatic Gluconeogenesis

FIGURE 4 | Er-Miao-Fang blocked hepatic cAMP and PKA induction. Mice were fed with chow diet or HFD for 10 days with oral administration of Er-Miao-Fang extracts (EMF, 1 g/kg) or metformin (Met, 200 mg/kg). BNL CL.2 hepatocytes were cultured in fat-derived CM from chow or HFD feeding mice or TNF-α antibody (1 µg/mL) and IL-1β antibody (0.6 µg/mL) treated with or without glucagon (100 nM) for 24 h. (A) PDE4B expression in liver tissue were detected by Western blot. The results were showed as the mean ± SD from four independent experiments. (B) cAMP in liver tissue were determined by ELISA kits (mean ± SD, n = 9–10). (C) Phosphorylation of PKA substrate in liver tissue was detected by Western blot. The results were showed as the mean ± SD from four independent experiments. (D) PDE4B expression in hepatocytes were determined by Western blot (n = 3) and (E) cAMP contents in the present of glucagon (100 nM) were measured by ELISA kits (n = 6). The results were expressed as the mean ± SD. *p < 0.05 vs. HFD feeding or HFD-CM or HFD-CM with glucagon treatment, #p < 0.05 vs. the indicated treatment. CM, conditioned medium.

expression and then effectively reduced cAMP accumulation by preserving PDE4B induction, resultant inhibiting PKA activity (Figures 4A–C). In view of the contribution of adipose dysfunction to hepatic gluconeogenesis (Perry et al., 2014), we prepared CM by incubation of adipose tissue of chow or HFD feeding mice and then incubated with hepatocytes. BNLCL.2 hepatocytes treated with HFD feeding mice-derived CM decreased PDE4B expression and increased glucagon-mediated cAMP accumulation in hepatocytes, but these effects were attenuated by co-treatment with TNF-α and IL-1β antibodies, suggesting that adipose dysfunction-derived inflammatory mediators impaired hepatic PDE4B to prevent cAMP degradation (Figures 4D,E). As expected, Er-Miao-Fang or metformin-derived CM effectively restored PDE4B protein expression and thus reduced cAMP accumulation in response to glucagon (Figures 4D,E). These results provided evidence that hepatic PDE4B induction was also impaired by inflammation partly and amelioration of adipose dysfunction might have the potential contribution to attenuate hepatic glucagon signaling.

Er-Miao-Fang Restrained Hepatic Glucagon Response

In response to cAMP/PKA signaling, the transcription factor cAMP-response element binding protein (CREB) is activated indicated by increased phosphorylation. Consistently, we observed CREB activation in liver of HFD-fed mice; however, oral administration of Er-Miao-Fang and metformin inhibited CREB activation by dephosphorylation (Figure 5A). To confirm the involvement of inflammation in CREB activation and downstream gene regulation, we co-incubated hepatocytes with adipose-derived CM. Glucagon promoted phosphorylated CREB translocation into the nucleus and this action was enhanced by co-treatment with CM derived from HFD-fed mice, but the increased phosphorylated CREB in the nucleus...
was reduced by neutralizing TNF-α and IL-1β with special antibodies (Figure 5B). CREB transcriptionally upregulates gene encoding gluconeogenesis. HFD feeding increased gene expressions of PGC-1α, Pepck, and G6pc in the liver, but the increased gene expressions were inhibited by Er-Miao-Fang and metformin administration (Figure 5C). When hepatocytes were exposed adipose-derived CM, Er-Miao-Fang and metformin, or TNF-α and IL-1β antibodies, suppressed gluconeogenetic gene expression (Figure 5D). We next showed that when hepatocytes were incubated with adipose-derived CM and antibodies of inflammatory factors at the same time, reduced hepatic glucose production in response to glucagon (Figure 5E). Together, these results might suggest that Er-Miao-Fang inhibited hepatic glucagon response in HFD-fed mice through inhibiting adipose inflammation.

DISCUSSION

Adipose dysfunction is closely related to metabolic diseases. Inflammatory mediators, including pro-inflammatory cytokines and FFAs, increase in the contents of FFAs in the blood circulation, linking adipose dysfunction and systemic insulin resistance in diabetes (Unger, 1995; Boden, 1999; Kim et al., 2001; Unger, 1995)
Zhao et al. Er-Miao-Fang Prevents Hepatic Gluconeogenesis

FIGURE 6 | The working pathway for Er-Miao-Fang inhibiting inflammation and blocking hepatic gluconeogenesis. HFD feeding induced inflammation and increased hepatic glucagon response, which leading to endogenous glucose production. Er-Miao-Fang inhibited inflammation and improved adipose dysfunction by preserving PDE3B and decreasing the accumulation of cAMP to prevent lipolysis. By blocking the traffic of fatty acids and inflammatory mediators from adipose tissue to the liver, Er-Miao-Fang inhibited the effect on hepatic gluconeogenesis through preserving PDE4B and reducing cAMP/PKA signaling.

Frayn, 2002). Herein, our work showed that Er-Miao-Fang might prevent adipose lipolysis by suppression of inflammation in adipose tissue, contributing to reducing excessive hepatic glucose output. This provides new insight into the role of Er-Miao-Fang in regulation of hepatic gluconeogenesis and presents the guiding significance for the regulation of multi-link targets with Traditional Chinese Medicine.

In the chief six components of prepared Er-Miao-Fang extracts, the main ingredients are alkaloids (Feng et al., 2017). Berberine and phellodendrine were reported to have the anti-inflammation activation. Short-term HFD induces adipose inflammation and adipose dysfunction, which is the upstream of crosstalk between adipose and liver. We found that berberine or phellodendrine inhibited the release of fatty acids from adipose tissue, while Er-Miao-Fang extracts prevented lipolysis even well. This suggested the potential advantages of Er-Miao-Fang extracts compared to berberine or phellodendrine in inhibiting lipolysis (Supplementary Figure 2), and it might be worth to discuss the superiority of Traditional Chinese Medical prescription in further study.

High-fat-diet feeding causes metabolic disorders. Actually, in our studies, lipolysis was induced by activating cAMP/PKA signaling. HFD-feeding enhanced PKA activation with an increase in cAMP accumulation and AMP reduction in adipocytes. As it has been known, cAMP is synthesized by AC and degraded by PDEs. Adenosine nucleosides are shown to inhibit AC activity (Fain et al., 1972). Er-Miao-Fang reduced cAMP accumulation with elevated levels of AMP in the fat of HFD-feeding mice, indicating that Er-Miao-Fang inhibited the expression of PKA and HSL phosphorylation to decreased lipolysis via attenuating cAMP/PKA signaling.

Phosphodiesterases activity was attenuated with cAMP accumulation, which was increased by pro-inflammatory cytokine TNF-α and NF-κB inflammatory signaling (Zhang et al., 2002; Degerman et al., 2011; Ke et al., 2015). So, it is necessary to investigate the relation of cAMP/PKA lipolysis signaling and inflammation in HFD-fed mice. cAMP is an important regulator of immune and inflammatory response, and turnover of intracellular cyclic nucleotides is dependent on the activity of PDEs (Oldenburger et al., 2012). In adipose tissue of obesity, TNF-α is found to impair the activity of PDE3B (Mei et al., 2002). Downregulation of PDE3B contributes to the mechanism whereby TNF-α induces lipolysis and excess release of FFAs (Rahn Landström et al., 2000). In our work, inflammation in adipose tissue of HFD-feeding mice was distinct, with the decrease of PDE3B expression. However, the decrease was removed by adding the TNF-α or IL-1β antibodies, indicating the contribution of inflammation to the activation of cAMP/PKA signaling. Er-Miao-Fang inhibited JNK activation with reduced inflammatory TNF-α and IL-1β release, and effectively preserved PDE3B activity. Also, Er-Miao-Fang showed the same effects with the neutralizing antibodies of inflammation factors, presenting that Er-Miao-Fang prevented lipolysis by inhibiting inflammation.

Obesity is characterized by low-grade inflammation, and chronic or continuous inflammation activates NF-κB signaling in adipose tissue and liver (Arkan et al., 2005; Cai et al., 2005; Donath and Shoelson, 2011). PDEs express not only in adipose, but also in liver (Abdollahi et al., 2003; Ke et al., 2015), and hepatic CAMP degradation is predominantly caused by PDE4B (Miller et al., 2013; Johanns et al., 2016). Recent studies demonstrated that PDE4B expression was associated with enhanced NF-κB activation and transcriptional activity. Indeed, we observed that expression of PDE4B was reduced in liver with adipose dysfunction. So, we next demonstrated that TNF-α and IL-1β antibodies preserved the PDE4B expression in BNL CL.2 hepatocytes, which was decreased by HFD fat-derived CM. Simultaneously, TNF-α and IL-1β antibodies decreased cAMP accumulation in hepatocytes activated by glucagon and HFD fat-derived CM. This data implied that adipose inflammation might...
link to the PDE4B expression, which induced hepatic cAMP degradation.

Er-Miao-Fang improved pyruvate tolerance in the HFD-fed mice, demonstrating its inhibitory effect on endogenous glucose production. Glucagon increases hepatic glucose output through gluconeogenesis mediated by activating cAMP/PKA signaling, which phosphorylates CREB protein. Phosphorylated CREB, together with different co-activators, translocates into the nucleus and stimulates transcription of gluconeogenic genes (Gonzalez and Montminy, 1989; Ravnskaer et al., 2007). Metformin, which is the first line therapeutic drug for diabetes to decrease blood glucose, triggers the dissociation of the CREB transcription complex and reduces gluconeogenic enzyme gene expression (He et al., 2009). For this, we observed the effect of Er-Miao-Fang on the glucagon response. Similar to metformin, Er-Miao-Fang decreased the phosphorylation status of CREB, the translocation to nucleus, gluconeogenic enzyme gene expression and glucose production in HFD-feeding mice liver tissue and hepatocytes stimulated by glucagon. Studies documented that overactivation of liver NF-κB-inducing kinase (NIK) enhanced hyperglycemia by increasing CREB stability in obese mice (Sheng et al., 2012). Interestingly, we further demonstrated that TNF-α and IL-1p antibodies lowered that effect, partly indicating the potential pathway that Er-Miao-Fang decreased hepatic CAMP/PKA gluconeogenesis signaling through inhibiting inflammation in HFD-feeding mice. However, this is should be further confirmed by blocking adipose inflammation or adopting adipose-specific PDE3B mutant mice in the future study.

It is noteworthy that inflammation-associated lipolysis occurred in short-term feeding and this could be the potential cause of insulin resistance and hepatic glucose production (Li et al., 2017). Also, our work showed that lipolysis occurred by inhibiting PDE3B and increasing cAMP activity in adipose, and this gives rise to suggesting that the product FFAs may have an effluence to glucose metabolism through other pathways to be proved. Overall, these may partly support the relevance of adipose inflammation and hepatic glucose production. However, the possibility that Er-Miao-Fang ameliorates inflammation in liver could not be excluded. Given that the feature of Traditional Chinese Medical may be of multi-link, it will be worth to pay attention to the explicit pathway that mediating glucose and lipid metabolism in the future study.

In summary, inflammation in adipose tissue might act as an important mediator to induce lipolysis and hepatic gluconeogenesis. Traditional Chinese Medical prescription Er-Miao-Fang prevented inflammation in adipose tissue and subsequent inhibited hepatic cAMP accumulation in liver contributing to restraint of the hepatic glucagon response (Figure 6). This study presents a new view of inhibiting inflammation to ameliorate glucose homeostasis and provides the guiding significance for the regulation of multi-link targets with Traditional Chinese Medicine.

AUTHOR CONTRIBUTIONS

NZ, BL, and JX designed the research. WZ performed experiments, analyzed, interpreted data, and drafted the manuscript. XF collected the data and reviewed the manuscript. NZ and JX edited the manuscript. BL contributed to the discussion of the manuscript. All authors approved the final version of the paper.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2018.01041/full#supplementary-material

REFERENCES

Abdollahi, M., Chan, T. S., Subrahmanyam, V., and O’Brien, P. J. (2003). Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycosynogenesis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol. Cell. Biochem. 252, 205–211.

Arkam, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z. W., Long, J. M., et al. (2011). From PDE3B to the regulation of energy homeostasis. Curr. Opin. Pharmacol. 11, 676–682. doi: 10.1016/j.coph.2011.09.015

Donath, M. Y., and Shoelson, S. E. (2011). Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98–107. doi: 10.1038/nrni2925

Fain, J. N., Pointer, R. H., and Ward, W. F. (1972). Effects of adenosine nucleosides on adenylate cyclase, phosphodiesterase, cyclic adenosine monophosphate accumulation, and lipolysis in fat cells. J. Biol. Chem. 247, 6866–6872.

Feng, X., Zhao, W., Hou, T., and Zhang, N. (2017). Simultaneous determination of 14 compounds in Er Miao San extracts by UPLC-MS/MS. Zhongguo Shi Yan Fang Ji Xue Za Zhi 23, 116–122.

Francis, S. H., Blount, M. A., and Corbin, J. D. (2011). Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev. 91, 651–690. doi: 10.1152/physrev.00030.2010

Frayn, K. N. (2002). Adipose tissue as a buffer for daily lipid flux. Diabetologia 45, 1201–1210. doi: 10.1007/s00125-002-0873-y

Gauthier, M. S., Miyoshi, H., Souza, S. C., Caccideo, J. M., Saha, A. K., Greenberg, A. S., et al. (2008). AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. J. Biol. Chem. 283, 16514–16524. doi: 10.1074/jbc.M708177200
Gonzalez, G. A., and Montminy, M. R. (1989). Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59, 675–680. doi: 10.1016/0092-8674(89)90013-3

Greenberg, A. S., Coleman, R. A., Kraemer, F. B., McNamara, J. L., Obin, M. S., Puri, V., et al. (2011). The role of lipid droplets in metabolic disease in rodents and humans. J. Clin. Invest. 121, 2102–2110. doi: 10.1172/JCI46069

Greenberg, A. S., Shen, W. J., Muliro, K., Patel, S., Souza, S. C., Roth, R. A., et al. (2001). Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J. Biol. Chem. 276, 45456–45461. doi: 10.1074/jbc.M104436200

He, L., Sabet, A., Djidjos, S., Miller, R., Sun, X., Hussain, M. A., et al. (2009). Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635–646. doi: 10.1016/j.cell.2009.03.016

Johanns, M., Lai, Y. C., Hsu, M. F., Jacobs, R., Vertommen, D., Van Sande, J., et al. (2017). Inhibition of miR-213-3p promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action. Nat. Med. 18, 943–949. doi: 10.1038/nm.2756

Lee, Y. S., Kim, W. S., Kim, K. H., Yoon, M. J., Cho, H. J., Shen, Y., et al. (2006). Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumor necrosis factor alpha and cAMP. Biochem. J. 394(Pt 2), 337–343. doi: 10.1042/BJ20050353

Lafontan, M., and Girard, J. (2008). Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab. Res. Rev. 55, 2256–2264. doi: 10.1038/sj.emboj.2601890

Lee, J. K., Fillmore, J. J., Chen, Y., Yu, C., Moore, I. K., Pypaert, M., et al. (2002). C(2)-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 adipocytes. J. Biol. Chem. 277, 32715–32723. doi: 10.1074/jbc.M202454200

Liu, H., Sabet, A., Djedjos, S., Miller, R., Sun, X., Hussain, M. A., et al. (2012). Cyclic AMP/PKA pathway in zebrafish embryos. J. Biol. Chem. 287, 45456–45461. doi: 10.1074/jbc.M112038200

Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., and Birnbaum, M. J. (2013). Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494, 256–260. doi: 10.1038/nature11808

Miyoshi, H., Souza, S. C., Zhang, H. H., Strissel, K. J., Christoffolete, M. A., Kovsan, J., et al. (2006). Perilipin promotes hormone-sensitive lipase-mediated adipocyte lipolysis via phosphorylation-dependent and -independent mechanisms. J. Biol. Chem. 281, 15837–15844. doi: 10.1074/jbc.M601097200

Oldenburger, A., Roscioni, S. S., Jansen, E., Menzen, M. H., Halyako, A. J., Timens, W., et al. (2012). Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease. PLoS One 7:e31574. doi: 10.1371/journal.pone.0031574

Perry, R. J., Samuel, V. T., Petersen, K. F., and Shulman, G. I. (2014). The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84–91. doi: 10.1038/nature13478

Rahn Landström, T., Mei, J., Karlsson, M., Manguinello, V., and Degerman, E. (2005). Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumor necrosis factor alpha and cAMP. Biochem. J. 384(Pt 2), 337–343. doi: 10.1042/BJ20030637

Ravnskjaer, K., Kester, H., Liu, Y., Zhang, X., Lee, D., Yates, J. R. III, et al. (2007). Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. EMBO J. 26, 2880–2889. doi: 10.1038/sj.emboj.7601715

Schweiger, M., Eichmann, T. O., Taschler, U., Zimmermann, R., Zechner, R., and Lass, A. (2014). Measurement of lipolysis. Methods Enzymol. 538, 171–193. doi: 10.1016/B978-0-12-800280-3.00010-4

Sheng, L., Zhou, Y., Chel, Z., Ren, D., Cho, K. W., Jiang, L., et al. (2012). NF-κB-induced kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action. Nat. Med. 18, 943–949. doi: 10.1038/nm.2756

Streep, R. S., Hornbuckle, L. A., Svitak, C. A., Goldman, J. K., Oser, J. K., and O’Brien, R. M. (2001). Protein kinase A phosphorylates hepatocyte nuclear factor-6 and stimulates glucagon-6-phosphatase catalytic subunit gene transcription. J. Biol. Chem. 276, 11911–11918. doi: 10.1074/jbc.M101144200

Unger, R. H. (1995). Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44, 863–870. doi: 10.2337/ dba.44.8.863

Unger, R. H., and Cherrington, A. D. (2012). Glucagononectric restructuring of diabetes: a pathophysiological and therapeutic makeover. J. Clin. Invest. 122, 4–12. doi: 10.1172/JCI60016

Wang, L., Zhang, B., Huang, F., Liu, B., and Xie, Y. (2016). Curcumin inhibits lipolysis via suppression of ER stress in adipose tissue and prevents hepatic insulin resistance. J. Lipid Res. 57, 1243–1255. doi: 10.1194/jlr.M067397

Wei, S., Zhang, M., Yu, Y., Lan, X., Yao, F., Yan, X., et al. (2016). Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incipubated HepG2 cells through suppression of the HNF-4α mRNA pathway. PLoS One 11:e0152097. doi: 10.1371/journal.pone.0152097

Xiao, N., Lou, M., Lu, Y., Yang, L., Liu, Q., Liu, B., et al. (2017). Ginsenoside Rg5 attenuates hepatic glucagon response via suppression of succinate-associated HIF-1α induction in HFD-fed mice. Diabetologia 60, 1084–1093. doi: 10.1007/s00125-017-4238-y

Yang, H., and Yang, L. (2016). Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy. J. Mol. Endocrinol. 57, R93–R108. doi: 10.1530/JME-15-0316

Zhang, H. H., Halbleib, M., Ahmad, F., Manguinello, V. C., and Greenberg, A. S. (2002). Tumor necrosis factor-a stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51, 2929–2935. doi: 10.1152/ajpendo.00228.2012

Zhao, W., Li, A., Feng, X., Hou, T., Liu, K., Liu, B., et al. (2016). Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. Cell. Signal. 28, 1401–1411. doi: 10.1016/j.cellsig.2016.06.018

Zhao, W., Wang, M., Shao, L., Liao, M., Liu, K., Huang, F., et al. (2014). The total phenolic fraction of Anemarrhena asphodeloides inhibits inflammation and reduces insulin resistance in adipocytes via regulation of AMP-kinase activity. Planta Med. 80, 146–152. doi: 10.1055/s-0033-1360197

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.